30 Day Trial
ORTHOKNOW logo

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

1Q14 Revenue: Medtronic

(fiscal year 2014 ended 4/25/14)

$3,041MM, -2% (U.S. $2,103MM, -4%; ex-U.S. $938MM, +4%)

  • Core Spine $2,570MM, flat (U.S. $1,694MM, -2%; ex-U.S. $876MM, +4%)
  • BMP $471MM, -11% (U.S. $409MM, -13%; ex-U.S. $62MM, +5%)

 

Quarterly revenue: $786MM, -2% (U.S. $534MM, -4%; ex-U.S. $252MM, +3%)

  • Core Spine $662MM, flat (U.S. $429MM, -2%; ex-U.S. $233MM, +2%)
  • BMP $124MM, -11% (U.S. $105MM, -14%; ex-U.S. $19MM, +11%)

 

  • Sales “meaningfully higher” in accounts that have adopted Surgical Synergy program
  • Market conditions stable, with some gradual improvement, principally coming out of the U.S.
  • U.S. pricing stable, down in the low- to mid-single-digits, offset by mix; procedures flat
  • 3 sequential quarters of stability for INFUSE, noting encouraging trends in U.S. balloon kyphoplasty